Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates
August proved to be a mixed month for regulatory approvals, with the Food and Drug Administration approving a few, turning down a few others and delaying the remaining.
38 Stocks Moving In Friday’s Mid-Day Session
Gainers
Regencell Bioscience Holdings Limited (NASDAQ: RGC) shares jumped 175% to $17.33. Regencell Bioscience reported partial exercise of underwriter’s over-allotment option.
The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen’s Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 19)
38 Stocks Moving In Thursday’s Mid-Day Session
Gainers
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) shares jumped 141% to $1.7950 after dropping 12% on Wednesday. Sonnet BioTherapeutics recently reported its financial results for the three months ended June 30th , 2021 and issued a business update.
46 Biggest Movers From Yesterday
Gainers
PharmaCyte Biotech, Inc. (NASDAQ: PMCB) shares climbed 189.5% to close at $9.90 on Wednesday after surging over 15% on Tuesday.
Impel NeuroPharma Q2 EPS $(0.79) Misses $(0.60) Estimate
Impel NeuroPharma (NASDAQ:IMPL) reported quarterly losses of $(0.79) per share which missed the analyst consensus estimate of $(0.60) by 31.67 percent.
78 Biggest Movers From Friday
Gainers
PharmaCyte Biotech, Inc. (NASDAQ: PMCB) shares jumped 43.4% to close at $3.27. PharmaCyte Biotech recently reported closing of $15-million public offering.
Earnings Scheduled For August 16, 2021
Companies Reporting Before The Bell
• Entera Bio (NASDAQ:ENTX) is likely to report earnings for its second quarter.
• Data Storage (NASDAQ:DTST) is expected to report earnings for its second quarter.
85 Biggest Movers From Yesterday
Gainers
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) jumped 125.3% to close at $18.77 on Tuesday after the company announced positive interim results from the Phase 1 trial with FTX-6058 in healthy adult volunteers.